Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 2Unknown 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3Observational 2

Sponsor

Cancer Type

Gynecologic 3

Conditions

Uterine Cervical Dysplasia 2Papillomavirus Infections 2Uterine Diseases 1Uterine Cervical Neoplasms 1Neoplasms 1Genital Diseases, Female 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 297Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × GX-188 vaccine × Clear all
NCT03444376 2025-07-30

The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer

Genexine, Inc.

Phase 1/2 Completed
65 enrolled 16 charts
Gynecologic

Uterine Cervical Neoplasms

NCT02139267 2017-07-12

Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia

Genexine, Inc.

Phase 2 Completed
72 enrolled
Gynecologic

Uterine Cervical Dysplasia, Genital Diseases, Female, Neoplasms, Uterine Diseases, Papillomavirus Infections

NCT02596243 2017-07-12

Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E)

Genexine, Inc.

Phase 2 Unknown
134 enrolled
Gynecologic

Uterine Cervical Dysplasia, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡